Angela Weyand
Pediatric Hematology-Oncology · Ann Arbor, MINPI 1558685180
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Sanofi at 54.5% of the total. Reporting peaked in 2023 at $139,355 and has fallen 91.5% since, to $11,853 in 2025. Among pediatric hematology-oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $1478.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$210K
- Takeda Pharmaceuticals U.S.A., Inc.$30K
- Genentech USA, Inc.$27K
- Swedish Orphan Biovitrum AB$24K
- F. Hoffmann-la Roche AG$16K
- Octapharma USA, Inc.$14K
- plus $65K from 12 others
Across 105 payments — averaging $7222.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$201K
- Sanofi US Services Inc.$178K
- Pfizer$175K
- Bioverativ Therapeutics Inc.$93K
- Sanofi$55K
- Novo Nordisk AS$38K
- plus $18K from 2 others
What the payments were for
- Consulting fees$191,87050%
- Speaking & faculty fees$111,83229%
- Travel & lodging$75,18220%
- Food & beverage$5,5601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 131 | $209,696 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $29,882 |
| Genentech USA, Inc. | 34 | $26,862 |
| Swedish Orphan Biovitrum AB | 5 | $23,526 |
| F. Hoffmann-la Roche AG | 6 | $16,227 |
| Octapharma USA, Inc. | 4 | $13,570 |
| Novo Nordisk | 8 | $10,189 |
| Genentech, Inc. | 7 | $9,145 |
| Sanofi US Services Inc. | 2 | $7,208 |
| Spark Therapeutics, Inc. | 8 | $7,101 |
| Pfizer | 2 | $6,500 |
| Bioverativ Therapeutics Inc. | 2 | $6,459 |
| Aptevo Therapeutics Inc | 6 | $4,367 |
| Bayer | 6 | $4,070 |
| HEMA Biologics, LLC | 1 | $3,350 |
| Kedrion Biopharma Inc. | 1 | $2,691 |
| CSL Behring | 4 | $1,915 |
| Biomarin Pharmaceutical Inc. | 6 | $1,686 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$384,444 in reported general payments places this provider in the 95th percentile of 84 pediatric hematology-oncology providers in Michigan.
See all pediatric hematology-oncology providers in Michigan →
Other pediatric hematology-oncology in Ann Arbor
- Steven PipeAnn Arbor$1.3M
- Jordan ShavitAnn Arbor$190K
- Andrew CampbellAnn Arbor$94K
- Kelly WalkovichAnn Arbor$43K
- Rajen ModyAnn Arbor$24K
- Andrea FransonAnn Arbor$18K
- Patrick GroharAnn Arbor$8K
- Ghada AbusinAnn Arbor$4K
- Gregory YanikAnn Arbor$3K
- Sharon SinghAnn Arbor$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.